Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.

Autor:	Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Kuroda Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Kanno T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Ueno A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Shiwa-Sudo N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Iwata-Yoshikawa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Sakai Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Nagata N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Arashiro T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Ainai A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Kishida N; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Watanabe S; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Nojima K; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Seki Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Hasegawa H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan., Ebihara H; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Fukushi S; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan., Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2023 May 19; Vol. 26 (5), pp. 106694. Date of Electronic Publication: 2023 Apr 19.
DOI:	10.1016/j.isci.2023.106694
Abstrakt:	Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infection, is challenging. To compare the impact of pre-Omicron to Omicron breakthrough infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2-4 months. The breadths of saturated cross-neutralization responses to Omicron lineages were comparable in pre-Omicron and Omicron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages. Competing Interests: The authors declare no competing interests. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu